HUTCHMED (China) Submits Blocklisting Six Monthly Return for 2015 and New 2026 Share Option Schemes

What the Blocklisting Six Monthly Return Means for HUTCHMED Shareholders

A blocklisting six monthly return is a regulatory filing required by the London Stock Exchange for companies that have obtained advance admission of securities to AIM under a block admission scheme — typically used to facilitate the exercise of employee share Options without the need for individual admission applications each time. The filing provides AIM investors with a transparent, periodic snapshot of how many shares have been issued under each scheme, how many remain outstanding, and whether the size of any block admission has changed. For HUTCHMED, the return covers two separate schemes and is dated 29 June 2026.

Because the filing touches directly on the potential Supply of new ordinary shares into the market, it carries relevance for investors monitoring dilution risk. While the number of shares actually issued or allotted during the six-month period was minimal — just 7,500 under the 2015 scheme — the establishment and block-listing of the 2026 scheme introduces a material new pool of potential share issuance that investors will need to incorporate into their analysis of the company's Capital/">Share Capital going forward.

The 2015 HUTCHMED Share Option Scheme: Minimal Allotments in the Latest Period

The 2015 HUTCHMED Share Option Scheme has been in operation for over a decade and was originally block-listed on AIM on 17 June 2019, following the company's share subdivision which took effect on 30 May 2019. At the time of that admission, 23,130,970 ordinary shares of US$0.10 each were listed under the scheme. The blocklisting was put in place to replace the company's previous block admission arrangement following the subdivision, ensuring continuity of the scheme's AIM compliance framework.

During the period covered by this return — 29 December 2025 to 28 June 2026 — only 7,500 ordinary shares were issued or allotted under the 2015 scheme. The announcement states that no increase was made to the block size during this period. As a result, the balance of shares under the 2015 scheme not yet issued or allotted at the end of the period stood at 45,768,368 ordinary shares, compared with the opening balance of 45,775,868 — reflecting the modest 7,500 issuance. The company did not disclose the exercise price or the identity of the option holders associated with those 7,500 shares in this announcement.

Introduction of the 2026 HUTCHMED Share Option Scheme and Its AIM Block Admission

A notable development disclosed in this return is the formal establishment of the 2026 HUTCHMED Share Option Scheme. The announcement states that this new scheme was adopted at the company's annual general meeting held on 12 May 2026, and that 43,616,756 ordinary shares of US$0.10 each were admitted to AIM under a block listing on 11 June 2026. The opening balance under the 2026 scheme in this return is therefore 43,616,756 shares, with nil having been issued or allotted by the end of the reporting period on 28 June 2026.

The introduction of a new share option scheme is consistent with standard practice for biopharmaceutical companies seeking to attract, retain, and incentivise scientific and commercial talent through equity-based remuneration. The size of the 2026 scheme's block admission — approximately 43.6 million shares — represents a meaningful addition to the overall pool of potential share issuances. The company did not disclose specific terms, vesting periods, or exercise prices relating to the 2026 scheme within this particular announcement.

Combined Scheme Balances and Their Relationship to Total Shares in Issue

Taking both schemes together, the total balance of ordinary shares not yet issued or allotted at 28 June 2026 amounts to 89,385,124 shares (comprising 45,768,368 under the 2015 scheme and 43,616,756 under the 2026 scheme). The total number of ordinary shares in issue at the end of the period is reported as 872,335,120. This means that the combined unissued balance under both schemes represents approximately 10.2% of the current issued share capital — a figure that investors may wish to Factor into assessments of potential future dilution should all outstanding options be exercised.

It is important to note that blocklisted shares do not automatically translate into new shares in circulation. Options must be exercised by eligible employees or beneficiaries before any shares are allotted, and exercise is typically conditional upon satisfaction of performance criteria, continued employment, and the applicable vesting schedule. The company did not disclose the proportion of options already granted versus those still available for future grant within either scheme.

HUTCHMED's Commercial and Scientific Context at the Time of This Filing

HUTCHMED describes itself as an innovative, commercial-stage biopharmaceutical company committed to the discovery, development, and commercialisation of targeted therapies and immunotherapies for cancer and immunological diseases. The company states that since inception it has focused on bringing drug candidates from in-house discovery through to patients around the world. Its first three medicines are marketed in China, and the announcement notes that the first of these has received approvals in the United States, Europe, and Japan — underscoring the company's ambition as a global oncology player rather than a purely regional entity.

The timing of this blocklisting return, filed at the end of June 2026, reflects the company's ongoing obligations under AIM Rules for Companies. The filing itself is procedural and administrative in nature, but it provides an important backdrop for understanding the scale of equity incentive arrangements currently in place. For a biopharmaceutical firm at HUTCHMED's stage of commercial development, maintaining competitive share option schemes is typically viewed as essential to retaining the highly specialised scientific and management expertise needed to advance a clinical and commercial pipeline.

AIM Regulatory Framework Behind the Blocklisting Requirement

Under the AIM Rules, companies that wish to have shares admitted to trading in advance of actual issuance — to facilitate prompt allotment upon option exercise — are required to obtain a block admission and to submit a six monthly return to the London Stock Exchange twice a year. This return must disclose the balance at the start of the period, any increases to the block, the number of securities issued during the period, and the remaining balance at the end of the period. HUTCHMED's filing dated 29 June 2026 fulfils this obligation for the reporting period ending 28 June 2026.

The blocklisting mechanism is widely used across AIM-listed companies, particularly those in the life sciences and technology sectors where share-based incentives form a core part of employee remuneration packages. By maintaining advance admission for these shares, HUTCHMED ensures that option exercises can be processed efficiently without triggering a separate admission application for each individual transaction, which would be both administratively burdensome and potentially disruptive to employees seeking to exercise their options.

Cross-Listing Considerations Across Nasdaq, AIM, and HKEX

HUTCHMED holds the relatively unusual distinction of being listed on three major exchanges simultaneously: the Nasdaq Global Select Market in the United States, AIM in the United Kingdom, and the Main Board of the Hong Kong Stock Exchange under stock code 13. The blocklisting six monthly return is a specific requirement of the AIM market, though the broader share option arrangements naturally affect the company's total equity structure across all three listings. Shareholders on all three exchanges share the same underlying class of ordinary shares, meaning that any allotment of shares under either option scheme has the same dilutive impact regardless of which market an investor holds their position on.

This multi-exchange presence reflects HUTCHMED's positioning as a globally oriented biopharmaceutical company seeking capital from, and visibility with, investors across Asia, Europe, and North America. The company's registered contacts for this announcement include addresses and telephone numbers in Hong Kong, alongside UK-based investor and media relations support from FTI Consulting and Brunswick, as well as AIM nominated adviser Panmure Liberum and joint Brokers Cavendish and Deutsche Numis.

Adviser and Broker Network Disclosed in the Announcement

The announcement identifies a well-established network of advisers supporting HUTCHMED's London market obligations. Panmure Liberum acts as Nominated Adviser and Joint Broker, with Atholl Tweedie, Emma Earl, and Rupert Dearden named as contacts. Cavendish serves as a joint broker, with Geoff Nash and Nigel Birks listed, whilst Deutsche Numis fulfils the same joint broker role through Duncan Monteith and Ramin Naji. The breadth of this broker panel is consistent with a company of HUTCHMED's scale and cross-market profile, ensuring coverage across different investor bases in the UK institutional and retail markets.

Media enquiries are directed to FTI Consulting and Brunswick, both prominent financial communications firms with significant experience in the healthcare and life sciences sectors. Ben Atwell and Tim Stamper at FTI, and Zhou Yi at Brunswick's Hong Kong office, are named as the respective contacts. The Investor relations function is handled directly by the company, with enquiries directed to the Hong Kong office at +852 2121 8200 or via the [email protected] email address.

Immediate Market Impact and Investor Considerations Going Forward

The immediate share price impact was not clear from available public information. Blocklisting six monthly returns are, by their nature, routine administrative filings and are rarely the primary catalyst for significant share price movement. However, the disclosure of the new 2026 HUTCHMED Share Option Scheme — representing a block admission of approximately 43.6 million shares — may prompt some investors to reassess their dilution modelling, particularly those who monitor changes to the equity incentive pool as part of their broader Investment analysis.

Investors may be watching for further announcements detailing the specific terms of the 2026 scheme, including exercise prices, performance conditions, and the identities of any key management or scientific personnel to whom options have been granted. Any material grants under the 2026 scheme would typically be disclosed through separate regulatory announcements in accordance with applicable rules across HUTCHMED's three listing venues. The next scheduled blocklisting six monthly return covering the 2026 scheme's first full reporting period would be expected in approximately six months' time.